News Snapshot:
We pointed out last week that China was a notable missing element in AstraZeneca’s COVID-19 vaccine strategy, despite being the drugmaker’s second-largest market. That has changed. AstraZeneca reached a licensing deal with Chinese firm BioKangtai to help provide its adenovirus vector-based COVID-19 vaccine candidate, created by the University of Oxford, to China, AstraZeneca said (Chinese) in a social media post on Thursday. The pair will also explore the possibility of producing the vaccine for other markets. Under the pact, AZ grants exclusive clinical development, production and commercialization rights to the vaccine in China to BioKangtai, which will in return reserve...
